All lobbying filings

THE NICKLES GROUP, LLC

Lobbying for AMGEN · Biotechnology.

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Oct 20, 2026

Income

$60,000

What the client paid this registrant for the period.

Client based in

California

Official filing document

Government bodies contacted 6

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 5

Taxation/Internal Revenue Code

Monitored implementation of H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act, as it relates to corporate taxes.

Trade (domestic/foreign)

Issues related to tariffs. Issues related to drug pricing.

Medicare/Medicaid

Monitored implementation of P.L. 117-169, the Inflation Reduction Act as it relates to drug pricing. Issues related to biosimilars. Monitored issues related to cardiovascular health. Issues related to pharmacy benefit management reforms. Monitored issues related to dialysis services. Issues related to the Most Favored Nation drug pricing.

Health Issues

Issues related to pharmacy benefit management reforms. Issues related to cardiovascular care. Issues related to drug pricing. Issues related to the drug supply chain. S. 3788, Clear Labels Act. S. 3014, Ensuring Timely Access to Generics Act of 2025; S. 1954, Biosimilar Red Tape Elimination Act; S. 2658, Medication Affordability and Patent Integrity Act.

Monitored issues related to intellectual property.

Bills named in this filing 5

H.R. 1
One Big Beautiful Bill Act
S. 3788
CLEAR LABELS Act
S. 3014
Ensuring Timely Access to Generics Act of 2025
S. 1954
Biosimilar Red Tape Elimination Act
S. 2658
Medication Affordability and Patent Integrity Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.